[198] Evaluation of GATA3 Expression in Tumors from Various Organs

Fan Lin, Jianhui Shi, Myra Wilkerson, Haiyan Liu. Geisinger Medical Center, Danville, PA

Background: GATA3 is a recently described immunohistochemical marker for urothelial carcinoma. Low GATA3 expression has also been suggested to correlate with poor prognosis in breast cancer. However, the published data on the GATA3 expression on tumors from other organs were limited. In this study, we investigated the expression of GATA3 in a large series of carcinomas from various organs using a single immunostaining system (Dako).
Design: Immunohistochemical evaluation of the expression of GATA3 (Santa Cruz Biotech Inc, Cat. No. GATA3 [HG3-31]:sc-268) on 1,110 cases of carcinomas from various organs using tissue mircroarray sections was performed. The staining intensity was graded as weak or strong. The distribution was recorded as negative (<5% of tumor cells stained), 1+ (5-25%), 2+ (26-50%), 3+ (51-75%), or 4+ (>75%).
Results: The positive staining results (%) and the total number of cases for each entity (N) are summarized in Table 1. Sixty-twoof 72 urothelial CA (86%), 90 of 99 ductal CA (91%) and 48 of 48 lobular CA were positive for GATA3. Diffuse (3+ or 4+) and strong nuclear staining was noted with 65% of urothelial CA, 84% of ductal CA and 77% of lobular CA. Two of 96 endometrial carcinoma cases were positive for GATA3. All others cases in this study were negative for GATA3.

Table 1. Summary of immunostaining results
TumorGATA3 (positive cases and %)
Seminoma (N=30)0
Embryonal CA (N=240
Yolk sac tumor (N=12)0
Lung neuroendocrine CA (N=61)0
Lung ADC (N=61)0
Lung SCC (N=49)0
Papillary thyroid CA (N=47)0
Follicular thyroid CA (N=37)0
Medullary thyroid CA (N=10)0
Anaplastic thyroid CA (N=5)0
Clear cell RCC (N=82)0
Papillary RCC (N=20)0
Colonic ADC (N=43)0
Esophageal ADC (N=30)0
Gastric ADC (N=21)0
Pancreatic ADC (N=50)0
Urothelial CA (N=31)62/72 (86%)
Prostatic ADC (N=136)0
Cholangiocarcinoma (N=11)0
Breast ductal CA (N=99)90/99 (91%)
Breast lobular CA (N=48)48/48 (100%0
Endocervical ADC (N=17)0
Endometrial CA (N= 96)2/96 (2%)
Ovarian serous CA (N=56)0
Hepatocellular CA (N=18)0
Pancreatic endocrine neoplasm (N=15)0
Skin melanoma (N=100)0
ADC–adenocarcinoma; CA–carcinoma; RCC–renal cell carcinoma

Conclusions: Our data demonstrate that GATA3 is a sensitive and specific marker for the diagnosis of urothelial carcinomas and breast carcinomas when working on a tumor of unknown origin. Caution should be taken in that rare cases of endometrial adenocarcinoma can be positive for GATA3 as well.
Category: Breast

Wednesday, March 21, 2012 1:00 PM

Poster Session VI # 18, Wednesday Afternoon


Close Window